ValuEngine upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a strong-buy rating in a research report released on Thursday morning.
Several other research analysts also recently weighed in on SGMO. Zacks Investment Research downgraded Sangamo Therapeutics from a hold rating to a strong sell rating in a research note on Tuesday, July 17th. Cowen reiterated a buy rating on shares of Sangamo Therapeutics in a research note on Monday, July 23rd. Wedbush reiterated a hold rating and set a $9.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. BidaskClub downgraded Sangamo Therapeutics from a hold rating to a sell rating in a research note on Thursday, July 26th. Finally, Guggenheim assumed coverage on Sangamo Therapeutics in a research note on Tuesday, October 9th. They set a buy rating and a $18.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $21.00.
NASDAQ:SGMO traded down $0.12 during trading on Thursday, reaching $13.79. The company’s stock had a trading volume of 15,645 shares, compared to its average volume of 1,643,793. The company has a market capitalization of $1.41 billion, a PE ratio of -19.39 and a beta of 3.21. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24. Sangamo Therapeutics has a 12 month low of $11.60 and a 12 month high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $21.42 million during the quarter, compared to the consensus estimate of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm’s revenue for the quarter was up 159.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS. Sell-side analysts anticipate that Sangamo Therapeutics will post -0.69 earnings per share for the current year.
In related news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $13.97, for a total transaction of $69,850.00. Following the sale, the chief financial officer now owns 12,250 shares of the company’s stock, valued at approximately $171,132.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director H Stewart Parker acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average cost of $13.52 per share, for a total transaction of $27,040.00. The disclosure for this purchase can be found here. Insiders have sold a total of 25,000 shares of company stock valued at $363,700 in the last quarter. 1.20% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virginia Retirement Systems ET AL purchased a new stake in Sangamo Therapeutics during the 3rd quarter worth about $678,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Sangamo Therapeutics during the 3rd quarter worth about $182,000. Wells Fargo & Company MN lifted its holdings in Sangamo Therapeutics by 12.7% during the 3rd quarter. Wells Fargo & Company MN now owns 890,234 shares of the biopharmaceutical company’s stock worth $15,089,000 after purchasing an additional 100,253 shares in the last quarter. Private Advisor Group LLC purchased a new stake in Sangamo Therapeutics during the 3rd quarter worth about $245,000. Finally, Russell Investments Group Ltd. lifted its holdings in Sangamo Therapeutics by 194.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 105,894 shares of the biopharmaceutical company’s stock worth $1,795,000 after purchasing an additional 69,984 shares in the last quarter. 64.01% of the stock is currently owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Read More: How accurate is the Rule of 72?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.